Cost-effectiveness of a Stepwise Approach vs Standard Care for Diabetes Prevention in India

• Published in: JAMA network open 2020-07, Vol.3 (7), p.e207539-e207539
• Main Authors: Islek, Duygu, Weber, Mary Beth, Ranjit Mohan, Anjana, Mohan, Viswanathan, Staimez, Lisa R, Harish, Ranjani, Narayan, K M Venkat, Laxy, Michael, Ali, Mohammed K
• Format: Article
• Language: English
• Subjects: Adult; Body Mass Index; Cost analysis; Cost-Benefit Analysis; Diabetes; Diabetes Mellitus, Type 2 - economics; Diabetes Mellitus, Type 2 - epidemiology; Diabetes Mellitus, Type 2 - prevention & control; Diabetes Mellitus, Type 2 - psychology; Female; Humans; Hypoglycemic Agents - therapeutic use; India - epidemiology; Lifestyles; Male; Mass Screening - methods; Mass Screening - organization & administration; Metformin - therapeutic use; National Health Programs - economics; National Health Programs - statistics & numerical data; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Risk Reduction Behavior
• ISSN: 2574-3805; 2574-3805
• DOI: 10.1001/jamanetworkopen.2020.7539

A stepwise approach that includes screening and lifestyle modification followed by the addition of metformin for individuals with high risk of diabetes is recommended to delay progression to diabetes; however, there is scant evidence regarding whether this approach is cost-effective. To estimate the cost-effectiveness of a stepwise approach in the Diabetes Community Lifestyle Improvement Program. This economic evaluation study included 578 adults with impaired glucose tolerance, impaired fasting glucose, or both. Participants were enrolled in the Diabetes Community Lifestyle Improvement Program, a randomized clinical trial with 3-year follow-up conducted at a diabetes care and research center in Chennai, India. The intervention group underwent a 6-month lifestyle modification curriculum plus stepwise addition of metformin; the control group received standard lifestyle advice. Cost, health benefits, and incremental cost-effectiveness ratios (ICERs) were estimated from multipayer (including direct medical costs) and societal (including direct medical and nonmedical costs) perspectives. Costs and ICERs were reported in 2019 Indian rupees (INR) and purchasing power parity-adjusted international dollars (INT $). The mean (SD) age of the 578 participants was 44.4 (9.3) years, and 364 (63.2%) were men. Mean (SD) body mass index was 27.9 (3.7), and the mean (SD) glycated hemoglobin level was 6.0% (0.5). Implementing lifestyle modification and metformin was associated with INR 10 549 (95% CI, INR 10 134-10 964) (INT $803 [95% CI, INT $771-834]) higher direct costs; INR 5194 (95% CI, INR 3187-INR 7201) (INT $395; 95% CI, INT $65-147) higher direct nonmedical costs, an absolute diabetes risk reduction of 10.2% (95% CI, 1.9% to 18.5%), and an incremental gain of 0.099 (95% CI, 0.018 to 0.179) quality-adjusted life-years per participant. From a multipayer perspective (including screening costs), mean ICERs were INR 1912 (INT $145) per 1 percentage point diabetes risk reduction, INR 191 090 (INT $14 539) per diabetes case prevented and/or delayed, and INR 196 960 (INT $14 986) per quality-adjusted life-year gained. In the scenario of a 50% increase or decrease in screening and intervention costs, the mean ICERs varied from INR 855 (INT $65) to INR 2968 (INT $226) per 1 percentage point diabetes risk reduction, from INR 85 495 (INT $6505) to INR 296 681 (INT $22 574) per diabetes case prevented, and from INR 88 121 (INT $6705) to INR 305 798 (INT $23 267) per quality-adj